首页> 外文OA文献 >International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update
【2h】

International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

机译:国际基础和临床药理学联盟。 LXXXI。腺苷受体的命名和分类—最新进展

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In the 10 years since our previous International Union of Basic and Clinical Pharmacology report on the nomenclature and classification of adenosine receptors, no developments have led to major changes in the recommendations. However, there have been so many other developments that an update is needed. The fact that the structure of one of the adenosine receptors has recently been solved has already led to new ways of in silico screening of ligands. The evidence that adenosine receptors can form homo- and heteromultimers has accumulated, but the functional significance of such complexes remains unclear. The availability of mice with genetic modification of all the adenosine receptors has led to a clarification of the functional roles of adenosine, and to excellent means to study the specificity of drugs. There are also interesting associations between disease and structural variants in one or more of the adenosine receptors. Several new selective agonists and antagonists have become available. They provide improved possibilities for receptor classification. There are also developments hinting at the usefulness of allosteric modulators. Many drugs targeting adenosine receptors are in clinical trials, but the established therapeutic use is still very limited.
机译:自我们上次国际基础与临床药理学联合会(International Union of Basic and Clinical Pharmacology)提出有关腺苷受体的命名法和分类的报告以来的10年中,没有任何进展导致建议的重大变化。但是,还有许多其他的发展需要更新。最近已经解决了一种腺苷受体结构的事实,这已经导致了计算机筛选配体的新方法。腺苷受体可以形成同型和异型多聚体的证据已经积累,但这种复合物的功能意义尚不清楚。对所有腺苷受体进行基因修饰的小鼠的可获得性已导致对腺苷功能作用的阐明,以及研究药物特异性的出色手段。一种或多种腺苷受体的疾病与结构变异之间也存在有趣的关联。几种新的选择性激动剂和拮抗剂已经可用。它们为受体分类提供了改进的可能性。也有一些发展暗示了变构调节剂的有用性。许多靶向腺苷受体的药物正在临床试验中,但是确定的治疗用途仍然非常有限。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号